In this study, we determined the association of 1180 non-synonymous single-nucleotide polymorphisms (SNPs) with systolic blood pressure (SBP) and hypertensive status. A total of 8842 subjects were taken from two community-based cohorts-Ansung (n ¼ 4183) and Ansan (n ¼ 4659), South Korea-which had been established for genome-wide association studies (GWAS). Five SNPs (rs16835244, rs2286672, rs6265, rs17237198 and rs7312017) were significantly associated (P-values: 0.003-0.0001, not corrected for genome-wide significance) with SBP in both cohorts. Of these SNPs, rs16835244 and rs2286672 correlated with risk for hypertension. The rs16835244 SNP replaces Ala288 in arginine decarboxylase (ADC) with serine, and rs2286672 replaces Arg172 in phospholipase D2 (PLD2) with cysteine. A comparison of peptide sequences between vertebrate homologues revealed that the SNPs identified occur at conserved amino-acid residues. In silico analysis of the protein structure showed that the substitution of a polar residue, serine, for a non-polar alanine at amino-acid residue 288 affects a conformational change in ADC, and that Arg172 in PLD2 resides in the PX domain, which is important for membrane trafficking. These results provide insights into the function of these non-synonymous SNPs in the development of hypertension. The study investigating non-synonymous SNPs from GWAS not only by statistical association analysis but also by biological relevance through the protein structure might be a good approach for identifying genetic risk factors for hypertension, in addition to discovering causative variations.
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Introduction
Blood pressure is an end-point clinical parameter, and 30-50% of the variability in blood pressure between individuals with hypertension is believed to be influenced by multiple genetic factors. 1 Hypertension is defined as blood pressure measurements of 140/90 mm Hg or greater, 2 and about 95% of hypertension, known as essential hypertension, is considered to be polygenic, resulting from the accumulation and combination of multiple genetic and environmental risks. 3 The candidate gene approach has been a principal strategy that has been used to identify the risk factors of essential hypertension. Candidate genes were selected from pathways that are implicated in blood pressure regulation-for example, the reninangiotensin system and the adrenergic system. 4 Polymorphisms in genes that control these systems have been examined for their association with hypertension, but replication studies [5] [6] [7] have failed to verify previously reported associations, presumably because of differences in demographics, such as age and ethnicity. 8 The first results of a genome-wide analysis of single-nucleotide polymorphism (SNP)-hypertension association were published by the Wellcome Trust Case-Control Consortium (WTCCC). 9 This study reported the six most significant SNPs that were associated with hypertension status, although none reached genome-wide significance (P-value o5 Â 10 À7 ). Unfortunately, replication studies of two other populations from the Family Blood Pressure Program 10 and the Korean Association REsource (KARE) 11 failed to confirm the majority of findings in the WTCCC. Despite the massive sequencing and exhaustive association analysis of the originally associated SNP locus, 12 it was difficult to identify any causative genetic variations. Determining these variations is important not only to understand the underlying associations between genotype and phenotype but also to apply the results in the development of diagnostic kits and drug design.
After the WTCCC study, several genome-wide association studies (GWASs) were reported for blood pressure regulation. A gene coding for a serine/ threonine kinase, STK39, was associated with blood pressure in the GWAS of the Old Order Amish, a small group of Swiss settlers in Pennsylvania (USA) in the 1700s.
13 CDH13, a cell-cell adhesion glycoprotein T-cadherin, was also mapped in the GWAS of the population-based KORA (Kooperative Gesundheitsforschung in der Region Augsburg) cohort recruited from Southern Germany.
14 In addition, two large meta-analyses of blood pressure GWA studies were published, conducted in subjects of European descent (Global Bpgen consortium, 34 433 subjects; 15 CHARGE consortium, 29 136 subjects 16 ). Both identified eight loci contributing significantly to BP levels.
Previously, we also reported ATP2B1, a plasma membrane calcium pump, associated with blood pressure in KARE (Korea Association Resource) GWAS. 17 In this study, 1180 non-synonymous SNPs that were selected from the KARE GWAS were reanalyzed in greater depth with regard to their association with elevated blood pressure and hypertension.
Materials and methods

Subjects
Subjects were taken from two community-based cohorts, Ansung and Ansan, in South Korea. Both cohorts were studied in 2001 as part of the Korean Genome Epidemiology Study (KoGES). In the previous report, we described subject characteristics, blood pressure measuring methods and genotyping methods. 17 In brief, the initial populations of individuals aged 40-69 years numbered 5018 from Ansung, a rural community, and 5020 from Ansan, an urban community. From the total of 10 038 participants, DNA was available from 10 004, all of whom were genotyped with the Affymetrix Genomewide Human SNP array 5.0 (Affymetrix Inc., Santa Clara, CA, USA). After excluding samples with low call rates (o96%, n ¼ 401), sample contamination (n ¼ 11), gender inconsistencies (n ¼ 41), cryptic relatedness (n ¼ 608) and serious concomitant illness (n ¼ 101), GWA genotypes from the remaining 8842 individuals were included in the association analysis. Of the 8842 subjects, 1291 had been treated with anti-hypertensive medications (n ¼ 961) or drugs that affected their blood pressure (n ¼ 330) and were excluded from the quantitative trait analysis, which was ultimately conducted in 7551 subjects.
For the case-control analysis of hypertension, 961 subjects who were on anti-hypertensive agents were included, yielding a final total of 1968 and 4452 controls, excluding pre-hypertensive subjects. Clinical information and genotype data were kindly provided by the Center for Genome Science KNIH, KCDC, Korea.
Clinical characteristics
The basic characteristics and blood pressure levels of patients are listed in Table 1 . For this study, blood pressure measurements were taken three times in the supine position. Regional differences were compared using the w 2 -test for sex ratio and hypertensive ratio and using the independent Student's t-test for age, body mass index, systolic blood pressure (SBP) and diastolic blood pressure (DBP).
Genotyping and quality control DNA samples were isolated from the peripheral blood of participants and genotyped with Affymetrix Genomewide Human SNP array 5.0; the quality control methods were described in the study by Cho et al. 17 Briefly, the accuracy of genotyping was examined by Bayesian Robust Linear Modeling using the Mahalanobis Distance (BRLMM) Genotyping Algorithm. 18 Samples with accuracies that were lower than 98% with a high missing genotype call rate (X4%), high heterozygosity (430%) or inconsistency in sex were excluded from subsequent analyses. Related individuals whose estimated identity-by-state values were high (40.80) 9 were also excluded. Consequently, the final sample size for the study was 8842 individuals.
If the genotyped SNPs had a high missing gene call rate (40.05) and low minor allele frequency (o0.01) and deviated significantly from the HardyWeinberg equilibrium (Po1 Â 10 À6 ), they were excluded. As a result, we analyzed 352 228 SNPs. The genotypes and clinical information were provided by the Center for Genome Science, KNIH, KCDC.
Statistical analysis
Using BIOMART version 5.0 (http://www.ensembl. org/biomart/), we selected 1180 non-synonymous SNPs from the QC-filtered 352 228 SNPs, on the basis of the information in dbSNP v.129. The BIOMART is a web-based tool, and allows the extraction of information from the most recently released database that limits on a specific category. In this case, we entered the 352 228 SNPs, limiting on non-synonymous category. Non-synonymous SNPs define nucleotide substitutions that result in amino-acid replacements. Linear regression analyses were performed using PLINK version 1.15 19 for SBP, after incorporating the cohort, age, sex and body mass index covariates. In the case-control study, we defined hypertensive cases as SBP X140 mm Hg and/or DBP X90 mm Hg. Normotensive cases, including individuals who were treated with anti-hypertension drugs and those who were healthy, were defined as SBP o120 mm Hg and DBP o80 mm Hg. All tests were performed on the basis of an additive, dominant or recessive model, and P-values were not adjusted for multiple tests. Homology search and in silico analysis of protein structure A homology search of orthologues was performed using NCBI BLAST in GenBank (http://www.ncbi. nlm.nih.gov). To identify the three-dimensional protein structure, the peptide sequences that were derived from the associated genes were used to scan the Protein Data Bank (PDB, http://www.pdb.org) and PFAM database (http://pfam.sanger.ac.uk). Examination of three-dimensional structures and their active sites was performed with GEMM 20 in silicon graphic workstation, Tezro R12000. The representations of three-dimensional structures were generated in MOLSCRIPT. 21 
Results
Association analysis of 1180 non-synonymous SNPs with SBP
The basic characteristics and blood pressure of the subjects in this study are listed in Table 1 . Of the 8842 individuals, 961 persons received anti-hypertensive therapy and 330 took medications that are likely to influence blood pressure. Therefore, we used the remaining 7551 subjects to analyze the association between the given SNPs and SBP. Age, sex and body mass index were included in the model as covariates.
A quantile-quantile plot of the trend test for SBP by SNP regression analysis is shown in Figure 1 . In Table 2 , the total numbers of significant SNPs that are associated with SBP (P-value o0.05) are described using three inheritance modes (additive, dominant and recessive). Among the SNPs tested, five showed consistent association with SBP in all three sample sets-the Ansung cohort, the Ansan cohort and the combination of cohorts (Table 3) . The genotyping clusters of these five SNPs are depicted in the Supplementary Figures. Considering the P-value and effect size, two of these SNPs (rs16835244 and rs17237198) seemed to follow the dominant mode of inheritance, and others (rs6265, rs7312017 and rs2286672) were likely to be recessive.
In our study, the rs16835244 SNP significantly increased SBP dominantly. The association signal plots around the significant non-synonymous SNP loci and the corresponding linkage disequilibria, generated with GWASaid (http://www.ngri.go.kr/cgi-bin/GWASaid/GWASaid. cgi) and Haploview 4.1 software, 22 are shown in Figure 2 . rs16835244, rs2286672 and rs6265 SNPs are located within the genes that encode arginine decarboxylase (ADC), phospholipase D2 (PLD2) and brain-derived neurotrophic factor precursor (BDNF), respectively. The other two SNPs, rs17237198 and rs7312017, reside in an unknown gene for a Bold values indicate significant P-values (P-value o0.05). protein that has a seven-transmembrane domain (AC089987.26-201, ENST00000328207), as described in the ENSEMBLE database (http://www.ensembl. org/index.html).
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Hypertension case-control study of SBP-associated SNPs We examined the five SNPs in a hypertension case-control study by logistic regression analysis.
The hypertensive cases were defined as SBP X140 mm Hg and/or DBP X90 mm Hg. Subjects who were treated with anti-hypertensive medications were included in this analysis. Normotensive controls were defined as SBP o120 mm Hg and DBP o80 mm Hg, excluding pre-hypertensive subjects (see Table 1 ). Of the five SNPs, rs16835244 and rs2286672 were significantly associated with hypertension in the Ansung and Ansan cohorts (Table 4 ). In silico analysis of predicted changes in protein structure caused by SNPs The SNP rs16835244 replaces Ala288 of ADC with serine (Table 5) . ADC is a paralogue of ornithine decarboxylase 1, which is 52% identical to the peptide sequence of human ADC (Figure 3a) . The structure of human ODC protein has been elucidated to 2.1 angstrom resolution. 23 ODC is predicted to form a homodimer (PDB_ID: 3btn) (Figure 3b) . Ala287 of ODC, the amino-acid equivalent of A288 in ADC, is likely to be buried in the homodimer, on the basis of the low percentage of wateraccessible surface on the residue (1% for the water-accessible surface of A287 in ODC, according to PDB prediction; data not shown). Notably, Ala288 is conserved between vertebrate orthologues of ADC (Figure 3c) .
The other SNP that is associated with hypertensive cases, rs2286672, replaces Ala172 in PLD2 with cysteine. Ala172 is in the PX domain of PLD2 (residues 68-192), which binds phosphoinositide in membrane trafficking. Ala172 is also well conserved between vertebrates (Figure 3d) .
Discussion
We performed a large-scale association analysis of 1180 non-synonymous SNPs that were extracted from Affymetrix SNP Array 5.0 with SBP and identified five SNPs (rs16835244, rs2286672, rs6265, rs17237198 and rs7312017) that consistently correlated with blood pressure in the Ansung, Ansan and combined samples. Of the five SNPs, rs16835244, rs2286672 and rs6265 are in known genes-ADC, PLD2 and BDNF, respectively. The other SNPs, rs17237198 and rs7312017, are in an unknown gene that encodes a seven-transmembrane protein (AC089987.26-201, ENST00000328207). Furthermore, the rs16835244 and rs2286672 SNPs in ADC and PLD2, respectively, are also associated with hypertension.
Although there are no significant SNPs after Bonferroni's correction, the genes including the SNPs seem to have biological functions in blood pressure regulation. ADC governs the metabolic pathway of arginine conversion into agmatine, the decarboxylated product of arginine. Agmatine, a putative neurotransmitter, regulates vascular smooth muscle tone. Agmatine is an endogenous ligand of imidazoline receptors, and human vascular smooth muscle cells express imidazoline receptors regulating vascular smooth muscle cell proliferation. 24 Another study indicated that agmatine induces cardiac sympatho-inhibition through the activation of both a-2-adrenoceptors and imidazoline I receptors. 25 In addition, the fact that it can regulate renal regulation of sympathetic tone is very important, 26 and most important of all, it can inhibit arginine vasopressin-stimulated urea transport in the rat inner medullary collecting duct. 27 These properties are closely related to the mechanism of hypertension. Recently, intravenous agmatine was reported to induce dose-dependent hypotension. [28] [29] [30] In our results, the rs16835244 SNP (A288S) in ADC was associated with a significant increase in blood pressure. We speculate that the change from alanine to serine at the 288th residue reduces the enzymatic activity of ADC, lowering the production of agmatine and increasing blood pressure.
We examined the well-studied protein structure of ODC, a paralogue of ADC, to assess the effect of SNP substitution. Because Ala288 varies inside the protein, the A288S substitution is unlikely to affect the binding of substrate or homodimerization. It can still affect the tertiary structure, however, with regard to the non-polar Phe41, Met383, Leu25 and Trp381 residues that surround Ala288 (data not shown).
The substitution of Ala288 with the polar serine residue can decrease the stability of ADC. We would like to determine the differences in the half-lives of ADC variants that are encoded by the two alleles. We also observed a disparity in the allelic frequency of rs16835244 between ethnic groups. Whereas the minor allelic frequency of rs16835244 was 0.068 in Koreans in this study, it was 0.111 in Han Chinese and 0.045 in Japanese. Yet, the rs16835244 SNP in ADC is not polymorphic in Caucasians and Africans, on the basis of the dbSNP database (http:// www.ncbi.nlm.gov/SNP), raising the issue of why and how this variant has survived only in Asian populations during evolution.
PLD2 hydrolyzes phosphatidyl choline to generate choline and the bioactive lipid phosphatidic acid and has been implicated in signal transduction, membrane trafficking, transformation and cytoskeletal reorganization. 31 Because PLD2 also regulates the endocytosis of angiotensin II receptor type 1 (AGTR1), 31 any impairment in PLD2 regulation may be associated with the development of hyperten- sion. 32 Results from this study provide evidence that the R98C genetic variant of PLD2 decreases blood pressure, as well as the risk for hypertension.
Arg98 lies in the PX domain (residues 68-192) of PLD2, which regulates membrane trafficking. A recent study reported that PLD2, localized to the plasma membrane, regulates AGTR1 endocytosis, which in turn mediates a specific signalling pathway. 33 We speculate that the R98C amino-acid change inhibits this localization, reducing the endocytosis of activated AGTR1. Consequently, constriction of blood vessels is reduced and blood pressure is lowered.
We also observed an association of rs6265 (V66M) in the BDNF gene with blood pressure. The V66M polymorphism has been reported to correlate with many diseases, such as Alzheimer, 34 Parkinson, 35 depression 36 and coronary artery malfunction. 37 BDNF is a member of the neurotrophin family of growth factors, which promote survival, differentiation and maintenance of neurons in the peripheral and central nervous system. 38 BDNF and its receptors are expressed in numerous cell types, including vascular smooth muscle cells, in which BDNF regulates vessel formation after vascular injury. 39 Most recent GWASs have used the P-value as the primary selection criterion to screen disease-associated SNPs. 9 Although these reports claim to have identified candidate genes for complex traits, it is still unclear how these variations affect phenotype. In an attempt to obtain more information on the function of genetic variations that are associated with blood pressure and hypertension, we investigated the potential influences of non-synonymous SNPs on protein structure by in silico analysis, using known homologues as references. Predictions on how protein structure will change as a consequence will guide future studies in determining the underlying mechanism of blood pressure regulation and in developing therapeutic medicines. What is known about this topic K Blood pressure is affected by multiple genes and environmental interactions.
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K Recently several genome-wide association studies have been performed on blood pressure and hypertension to identify the genetic factors.
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What this study adds K This study provides an opportunity to identify causative non-synonymous genetic variations in a hypertension genome-wide association study. K On the basis of previous reports, newly identified genes ADC, PLD2 and BDNF seem to be relevant to hypertension, suggesting the reliability of this approach. K Therefore, the addition of these genes to the list of genetic risk factors in hypertension will increase the understanding of the genetic architecture for the development of hypertension.
